Twenty-hour donor platelet recoveries for platelets prepared from combined F-LR + MPR treatments of PRP. (A) Seven of 8 (88%) recipients of PLS-5A F-LR + MPR accepted treated transfusions and 2 of 7 (30%) accepting recipients also accepted subsequent standard platelet transfusions from their same donor. There was no difference between means of pretreatment (53% ± 12%) and posttreatment (57% ± 13%) autologous platelet recoveries (P = .52), but there was a significant difference between pretreated and treated (33% ± 9%) autologous platelet recoveries (P < .001). (B) All 7 recipients of PL1-B F-LR + MPR accepted treated donor transfusions, and 3 of 7 (43%) recipients also accepted subsequent standard transfusions from their same donor. There were no differences between means of pretreatment (46% ± 9%) and posttreatment (52% ± 9%) autologous platelet recoveries (P = .31), nor between pretreated and treated (43% ± 7%) autologous platelet recoveries (P = .56). (C) All 7 recipients of F-LR + MPR + γ-I accepted treated transfusions, and 2 of 7 (29%) also accepted subsequent standard transfusions from their same donor. Four of the donors’ platelets were PL1-B F-LR, and 3 were PLS-5A F-LR. There were no differences between means of pretreated (53% ± 6%) and treated (39% ± 7%) autologous platelet recoveries (P = .11).